

Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals), Region - Global Forecast to 2030

Market Report | 2025-05-09 | 713 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global Artificial Intelligence (AI) in healthcare market is projected to reach USD 110.61 billion by 2030 from USD 21.66 billion in 2025, at a CAGR of 38.6% during the forecast period. The market is expected to grow due to the growing investments & funding by public-private organizations, the fast proliferation of AI in the healthcare industry, and the rising focus on developing human-aware AI systems. The market has experienced growth due to increasing demand for enhanced services due to an unequal ratio between the healthcare workforce and patient numbers. However, inadequate IT infrastructure and unwillingness to adopt AI-based healthcare solutions in emerging economies are estimated to pose a challenge to market growth.

By deployment, the cloud-based segment is expected to register the highest growth during the forecast period. The AI in healthcare market is categorized into three deployment models: on-premise, cloud-based, and hybrid models. The cloud-based models segment holds the largest share due to the scalability, cost-effectiveness, and accessibility of these models. Cloud-based models facilitate real-time data processing and collaboration. They allow for seamless integration, secure data storage, and rapid deployment, making them particularly suitable for healthcare providers and payers. They provide faster, more reliable care while maintaining high-quality standards. Cloud-based AI solutions are becoming increasingly popular due to their cost-effectiveness, scalability, and support for remote access. These solutions enable seamless integration and real-time analytics. The growing adoption of telehealth and advancements in healthcare IT infrastructure further drive the demand for cloud-based models.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

By end user, the hospitals & clinics segment dominated the market in the Artificial Intelligence (AI) in healthcare market for healthcare providers in 2024.

By end user, Artificial Intelligence (AI) in healthcare market is segmented into hospitals & clinics, ambulatory surgical centers, home healthcare agencies & assisted living facilities, diagnostic & imaging centers, pharmacies, and other healthcare providers. The hospitals & clinics segment accounted for the largest share of the Artificial Intelligence (AI) in healthcare market. This is attributed to the increasing demand for personalized medicines, precise diagnostics & surgical planning, growth in minimally-invasive procedures, and the requirement for interoperability with existing systems. AI-based healthcare solutions enhance diagnostic accuracy, streamline operations, and personalize care in hospitals and clinics. They automate administrative tasks, predict patient outcomes, and enable faster decision-making with real-time data analysis. AI also supports remote monitoring, optimizes resources, and reduces costs by minimizing unnecessary treatments. AI improves patient engagement through virtual assistants and enhances security by detecting fraud, making healthcare more efficient, accessible, and cost-effective.

Asia Pacific is expected to register the highest growth during the forecast period.

The Artificial Intelligence (AI) in healthcare market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to register the highest growth during the forecast period. The Asia Pacific (APAC) region is experiencing substantial growth in the adoption of AI technologies within the healthcare sector, driven by a combination of demographic shifts, technological advancements, and increased investments in innovation. The rising elderly population in the Asia Pacific is a key factor, with the proportion of individuals aged 65 years and above increasing significantly. According to the UN's World Population Aging 2020 report, the global population in this age group is expected to double from 727 million in 2020 to 1.5 billion by 2050, with Eastern and Southeastern Asia contributing a large share of this growth.

The break-down of primary participants is as mentioned below:

-□By Company Type - Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%

-□By Designation - Directors: 30%, Manager: 34%, and Others: 36%

-□By Region - North America: 40%, Europe: 28%, Asia Pacific: 20%, Latin America: 7% and Middle East & Africa: 5%

Key Players

The prominent players operating in the Artificial Intelligence (AI) in healthcare market include Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US), GE Healthcare (US), Medtronic (US), Oracle (US), Veradigm LLC (US), Merative (IBM) (US), Google (US), Cognizant (US), Johnson & Johnson (US), Amazon Web Services, Inc. (US), SOPHiA GENETICS (US), Riverian Technologies (US), Terarecon (ConcertAI) (US), Solventum Corporation (US), Tempus (US), Viz.ai (US). These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers, and acquisitions to strengthen their market presence in the Artificial Intelligence (AI) in healthcare market.

Research Coverage

The report analyzes the Artificial Intelligence (AI) in healthcare market and aims to estimate the market size and future growth potential of various market segments based on offering, solution type, imaging modality, application, end user, and region. The report also analyzes factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market stakeholders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Artificial Intelligence (AI) in healthcare market. The report forecasts the revenue of the market segments with respect to five major regions. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a higher market share. Firms purchasing the report could use one or a combination of the following

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

strategies to strengthen their positions in the market.

This report provides insights on:

- Analysis of key drivers (exponential growth in data volume and complexity due to surging adoption of digital technologies, significant cost pressure on healthcare service providers with increasing prevalence of chronic diseases, rapid proliferation of AI in healthcare sector, growing need for improvised healthcare services, growing need for early detection and diagnosis, restraints (reluctance among medical practitioners to adopt AI-based technologies, shortage of skilled AI professionals handling AI-powered solutions, lack of standardized frameworks for AI and ML technologies), opportunities (increasing use of AI-powered solutions in elderly care, increasing focus on developing human-aware AI systems, strategic partnerships and collaborations among healthcare companies and AI technology providers), challenges (inaccurate predictions due to scarcity of high-quality healthcare data, concerns regarding data privacy, lack of interoperability between AI solutions offered by different vendors) are factors contributing the growth of the Artificial Intelligence (AI) in healthcare market
- Product Development/Innovation: Detailed insights into upcoming trends, research & development activities, and software launches in the Artificial Intelligence (AI) in healthcare market
- Market Development: Comprehensive information on the lucrative emerging markets, type of solution, component, deployment model, industry, and region
- Market Diversification: Exhaustive information about software portfolios, growing geographies, recent developments, and investments in the Artificial Intelligence (AI) in healthcare market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Artificial Intelligence (AI) in healthcare market, such as Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US)

Table of Contents:

1□INTRODUCTION□	58
1.1□STUDY OBJECTIVES□	58
1.2□MARKET DEFINITION□	58
1.3□STUDY SCOPE□	59
1.3.1□MARKETS COVERED□	59
1.3.2□INCLUSIONS & EXCLUSIONS□	60
1.3.3□YEARS CONSIDERED□	63
1.4□CURRENCY CONSIDERED□	64
1.5□STAKEHOLDERS□	64
2□RESEARCH METHODOLOGY□	65
2.1□RESEARCH DATA□	65
2.1.1□SECONDARY DATA□	66
2.1.1.1□Key data from secondary sources□	67
2.1.2□PRIMARY DATA□	67
2.1.2.1□Key industry insights□	69
2.2□MARKET SIZE ESTIMATION□	70
2.3□DATA TRIANGULATION□	76
2.4□MARKET SHARE ESTIMATION□	77
2.5□STUDY ASSUMPTIONS□	77
2.6□LIMITATIONS□	77
2.6.1□METHODOLOGY-RELATED LIMITATIONS□	77
2.6.2□SCOPE-RELATED LIMITATIONS□	77
2.7□RISK ASSESSMENT□	78
3□EXECUTIVE SUMMARY□	79

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4	PREMIUM INSIGHTS	85
4.1	AI IN HEALTHCARE MARKET OVERVIEW	85
4.2	ASIA PACIFIC: AI IN HEALTHCARE, BY OFFERING AND COUNTRY	86
4.3	AI IN HEALTHCARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	87
4.4	AI IN HEALTHCARE MARKET: REGIONAL MIX	87
4.5	AI IN HEALTHCARE: DEVELOPED VS. EMERGING MARKETS	88
5	MARKET OVERVIEW	89
5.1	INTRODUCTION	89
5.2	MARKET DYNAMICS	89
5.2.1	DRIVERS	90
5.2.1.1	Increase in need for early detection and diagnosis	90
5.2.1.2	Exponential growth in data volume and complexity due to surging adoption of digital technologies	91
5.2.1.3	Significant cost pressure on healthcare service providers with increasing prevalence of chronic diseases	91
5.2.1.4	Rapid proliferation of AI in healthcare sector	92
5.2.1.5	Growth in need for improvised healthcare services	93
5.2.2	RESTRAINTS	93
5.2.2.1	Reluctance among medical practitioners to adopt AI-based technologies	93
5.2.2.2	Shortage of skilled AI professionals handling AI-powered solutions	94
5.2.2.3	Lack of standardized frameworks for AI and ML technologies	94
5.2.3	OPPORTUNITIES	95
5.2.3.1	Increasing use of AI-powered solutions in elderly care	95
5.2.3.2	Increase in focus on developing human-aware AI systems	95
5.2.3.3	Strategic partnerships and collaborations among healthcare companies and AI technology providers	96
5.2.4	CHALLENGES	97
5.2.4.1	Inaccurate predictions due to scarcity of high-quality healthcare data	97
5.2.4.2	Concerns regarding data privacy	98
5.2.4.3	Lack of interoperability between AI solutions offered by different vendors	99
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	100
5.4	TECHNOLOGY ANALYSIS	101
5.4.1	KEY TECHNOLOGIES	101
5.4.1.1	Machine learning (ML) and deep learning	101
5.4.1.2	Natural language processing (NLP)	101
5.4.1.3	Computer vision (CV)	101
5.4.2	COMPLEMENTARY TECHNOLOGIES	102
5.4.2.1	Cloud computing	102
5.4.2.2	Digital twins	102
5.4.2.3	Robotic process automation (RPA)	102
5.4.3	ADJACENT TECHNOLOGIES	102
5.4.3.1	Blockchain	102
5.4.3.2	Augmented and virtual reality (AR/VR)	103
5.4.3.3	Internet of things (IoT)	103
5.5	INDUSTRY TRENDS	103
5.5.1	SHIFT TOWARD PERSONALIZED MEDICINE	103
5.5.2	AI IN DIAGNOSTICS AND IMAGING	104
5.6	PRICING ANALYSIS	104
5.6.1	INDICATIVE PRICING OF AI IN HEALTHCARE SOFTWARE, BY DEPLOYMENT MODEL (QUALITATIVE)	105
5.6.2	INDICATIVE PRICING OF AI IN HEALTHCARE SOFTWARE, BY REGION (QUALITATIVE)	105

5.7	VALUE CHAIN ANALYSIS	106
5.8	ECOSYSTEM ANALYSIS	107
5.9	PATENT ANALYSIS	110
5.9.1	INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS	110
5.10	KEY CONFERENCES & EVENTS	114
5.11	CASE STUDY ANALYSIS	115
5.11.1	BIOBEAT LAUNCHED HOME-BASED REMOTE PATIENT MONITORING KIT DURING PEAK WAVE OF COVID-19	115
5.11.2	MICROSOFT COLLABORATED WITH CLEVELAND CLINIC TO APPLY PREDICTIVE AND ADVANCED ANALYTICS TO IDENTIFY POTENTIAL AT-RISK PATIENTS UNDER ICU CARE	116
5.11.3	TGEN COLLABORATED WITH INTEL CORPORATION AND DELL TECHNOLOGIES TO ASSIST PHYSICIANS AND RESEARCHERS IN ACCELERATING DIAGNOSIS AND TREATMENT AT LOWER COSTS	116
5.11.4	GE HEALTHCARE IMPROVED PATIENT OUTCOMES BY REDUCING WORKFLOW PROCESSING TIME USING MEDICAL IMAGING DATA	117
5.12	REGULATORY LANDSCAPE	117
5.12.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	117
5.12.2	REGULATORY FRAMEWORK	120
5.12.2.1	North America	120
5.12.2.2	Europe	122
5.12.2.3	Asia Pacific	122
5.12.2.4	Middle East & Africa	123
5.12.2.5	Latin America	124
5.13	PORTER'S FIVE FORCES ANALYSIS	124
5.13.1	THREAT OF NEW ENTRANTS	125
5.13.2	THREAT OF SUBSTITUTES	126
5.13.3	BARGAINING POWER OF SUPPLIERS	126
5.13.4	BARGAINING POWER OF BUYERS	126
5.13.5	INTENSITY OF COMPETITIVE RIVALRY	126
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	127
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	127
5.14.2	BUYING CRITERIA	128
5.15	END-USER ANALYSIS	129
5.15.1	UNMET NEEDS	129
5.15.2	END-USER EXPECTATIONS	130
5.16	AI IN HEALTHCARE BUSINESS MODELS	131
5.16.1	SOFTWARE-AS-A-SERVICE (SAAS) MODEL	131
5.16.2	LICENSING MODEL	131
5.16.3	REVENUE SHARING/OUTCOME-BASED MODEL	131
5.16.4	FREEMIUM MODEL	131
5.16.5	AI-AS-A-SERVICE (AIAAS) MODEL	131
5.16.6	PARTNERSHIP/REVENUE-SHARING MODEL	132
5.16.7	HYBRID MODELS	132
5.16.8	PAY-PER-USE MODELS	132
5.17	INVESTMENT & FUNDING SCENARIO	132
5.18	IMPACT OF GENERATIVE AI ON AI IN HEALTHCARE MARKET	133
5.18.1	INTRODUCTION	133
5.18.2	MARKET POTENTIAL OF GEN AI IN HEALTHCARE	133
5.18.2.1	Key use cases of Gen AI	134

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.18.3	CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION	135
5.18.3.1	Eka Care leveraging generative AI for improved health outcomes	135
5.18.4	INTERCONNECTED AND ADJACENT ECOSYSTEMS	136
5.18.4.1	AI in healthcare IT	137
5.18.4.2	AI in medical diagnostics	137
5.18.4.3	AI in oncology	138
5.18.4.4	AI in clinical trials	138
5.18.4.5	AI in drug discovery	138
5.18.5	USER READINESS & IMPACT ASSESSMENT	139
5.18.5.1	User readiness	139
5.18.5.1.1	Healthcare providers	139
5.18.5.1.2	Healthcare payers	139
5.18.5.1.3	Patients	139
5.18.5.2	Impact assessment	140
5.18.5.2.1	User A: Healthcare providers	140
5.18.5.2.1.1	Implementation	140
5.18.5.2.1.2	Impact	140
5.18.5.2.2	User B: Healthcare payers	140
5.18.5.2.2.1	Implementation	140
5.18.5.2.2.2	Impact	141
5.18.5.2.3	User C: Patients	141
5.18.5.2.3.1	Implementation	141
5.18.5.2.3.2	Impact	141
6	IMPACT OF 2025 US TARIFF - OVERVIEW	142
6.1	INTRODUCTION	142
6.2	KEY TARIFF RATES	142
6.3	PRICE IMPACT ANALYSIS	143
6.4	IMPACT ON COUNTRY/REGION	144
6.4.1	US	144
6.4.2	EUROPE	145
6.4.3	ASIA PACIFIC	145
6.5	IMPACT ON END-USE INDUSTRIES	146
7	AI IN HEALTHCARE MARKET, BY OFFERING	147
7.1	INTRODUCTION	148
7.2	INTEGRATED SOLUTIONS	148
7.2.1	RISE IN WORKFORCE CHALLENGES AND COST PRESSURES TO DRIVE ADOPTION	148
7.3	NICHE/POINT SOLUTIONS	149
7.3.1	TARGETED AI SOLUTIONS TRANSFORMING PRECISION CARE AND EFFICIENCY IN HEALTHCARE TO BOOST MARKET	149
7.4	AI TECHNOLOGIES	150
7.4.1	ABILITY OF CORE AI TECHNOLOGIES TO DRIVE PRECISION, EFFICIENCY, AND INNOVATION TO SUPPORT MARKET GROWTH	150
7.5	SERVICES	151
7.5.1	NEED TO EMPOWER NON-CLINICAL HEALTHCARE OPERATIONS TO FUEL MARKET GROWTH	151
8	AI IN HEALTHCARE MARKET, BY FUNCTION	153
8.1	INTRODUCTION	154
8.2	DIAGNOSIS & EARLY DETECTION	154
8.2.1	PRE-SCREENING	156

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2.1.1	Early detection, better outcomes, and cost-effective care associated with pre-screening to boost market	156
8.2.2	IVD	156
8.2.2.1	IVD market, by technology	157
8.2.2.1.1	Immunoassays	158
8.2.2.1.1.1	Increase in focus on earlier disease detection & personalized treatment planning to drive market	158
8.2.2.1.2	Clinical chemistry	158
8.2.2.1.2.1	Increased demand for precision and personalized medicine and efficient healthcare systems to drive market	158
8.2.2.1.3	Molecular diagnostics	159
8.2.2.1.3.1	Improved disease detection, personalized treatments, and enhanced outcomes to fuel growth	159
8.2.2.2	IVD market, by application	160
8.2.2.2.1	Image analysis & interpretation	160
8.2.2.2.1.1	Advantages such as enhanced diagnostic accuracy, faster detection, and improved patient outcomes to support growth	160
8.2.2.2.2	Biomarker discovery & analysis	161
8.2.2.2.2.1	Ability of AI-based biomarker discovery to enhance disease detection, prognosis, and personalized treatment to drive adoption	161
8.2.2.2.3	Other IVD applications	162
8.2.3	DIAGNOSTIC IMAGING	162
8.2.3.1	Diagnostic imaging market, by application	163
8.2.3.1.1	Disease interpretation & report analysis	164
8.2.3.1.1.1	Ability of AI-driven disease interpretation to accelerate diagnosis, treatment, and outcomes to fuel growth	164
8.2.3.1.2	Image captioning & annotation	164
8.2.3.1.2.1	Enhanced diagnostic accuracy, efficiency, and consistency associated with image captioning & annotation to boost market	164
8.2.3.1.3	Image reconstruction	165
8.2.3.1.3.1	Improved diagnostic precision, efficiency, and image quality in healthcare to drive market	165
8.2.3.1.4	Other diagnostic imaging applications	166
8.2.3.2	Diagnostic imaging market, by modality	166
8.2.3.2.1	Magnetic resonance imaging (MRI)	167
8.2.3.2.1.1	Rise in technological advancements to drive adoption of AI in MRI	167
8.2.3.2.2	Computed tomography (CT)	168
8.2.3.2.2.1	Increase in availability of cardiac CT devices enabled with AI solutions to drive market	168
8.2.3.2.3	X-ray imaging	169
8.2.3.2.3.1	Innovative AI solutions for X-ray imaging by key players to drive market	169
8.2.3.2.4	Ultrasound	170
8.2.3.2.4.1	Increase in prevalence of and need for early detection of ovarian cancer to drive market	170
8.2.3.2.5	Nuclear imaging (PET & SPECT)	171
8.2.3.2.5.1	Critical role played by PET and SPECT in visualizing metabolic processes to contribute to growth	171
8.2.3.2.6	Other diagnostic imaging modalities	171
8.2.4	RISK ASSESSMENT & PATIENT STRATIFICATION	172
8.2.4.1	AI-driven risk assessment and patient stratification to enhance healthcare efficiency, outcomes, and personalized care	172
8.2.5	DRUG ALLERGY ALERTING	173
8.2.5.1	Ability of AI-enhanced drug allergy alerting to improve accuracy and patient safety to boost market	173
8.2.6	OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS	174
8.3	TREATMENT PLANNING & PERSONALIZATION	175
8.3.1	PERSONALIZED TREATMENT PLANNING	176
8.3.1.1	Precision medicine & genomic analysis	177

8.3.1.1.1	Advantages such as accurate disease predictions and improved outcomes to drive demand	177
8.3.1.2	Predictive models for treatment response	178
8.3.1.2.1	Ability to personalize therapies, improve outcomes, and minimize adverse effects to fuel growth	178
8.3.1.3	Treatment recommendation systems	179
8.3.1.3.1	Optimized healthcare delivery associated with treatment recommendation systems to support growth	179
8.3.2	PHARMACOLOGICAL THERAPY	180
8.3.2.1	Drug response prediction	181
8.3.2.1.1	Growth in use of drug response prediction to minimize adverse reactions to drive segment	181
8.3.2.2	Dosing & administration	181
8.3.2.2.1	Improved efficacy with highly personalized administration care to fuel adoption	181
8.3.2.3	Other pharmacological therapy functions	182
8.3.3	SURGICAL THERAPY	183
8.3.3.1	Preoperative imaging & 3D modeling	184
8.3.3.1.1	Enhanced surgical planning and precision to propel market	184
8.3.3.2	Intraoperative guidance & robotics	184
8.3.3.2.1	Faster recovery time post surgery to boost adoption	184
8.3.3.3	Postoperative analysis & recovery	185
8.3.3.3.1	Reduced complications with real-time monitoring to drive market	185
8.3.4	RADIATION THERAPY	186
8.3.4.1	Motion synchronization & auto contouring	187
8.3.4.1.1	Optimized radiation therapy with motion synchronization & auto contouring to boost market	187
8.3.4.2	Real-time adaptive treatment delivery	188
8.3.4.2.1	Reduced side effects with effective adaptive treatment to propel demand	188
8.3.4.3	Response assessment & quality assurance	188
8.3.4.3.1	Ability of AI to enhance response assessment and QA to spur growth	188
8.3.4.4	Other radiation therapy functions	189
8.3.5	BEHAVIORAL THERAPY & PSYCHOTHERAPY	190
8.3.5.1	Virtual counseling & chatbots	191
8.3.5.1.1	Ability to engage patients remotely to drive market demand	191
8.3.5.2	Progress monitoring & feedback	191
8.3.5.2.1	Increasing use of smart wearables and mobile health apps to drive market	191
8.3.5.3	Follow-up & long-term support	192
8.3.5.3.1	Widespread adoption of telemedicine platforms to drive market demand	192
8.3.6	IMMUNOTHERAPY	193
8.3.6.1	Real-time patient data monitoring	194
8.3.6.1.1	Need for real-time data analysis to make informed decisions to boost market growth	194
8.3.6.2	Response & side-effect prediction	195
8.3.6.2.1	Ability to reduce trial-and-error approach in medical treatments to drive segmental growth	195
8.3.6.3	Relapse prediction & long-term management	195
8.3.6.3.1	Need for proactive approach for long-term care to fuel market growth	195
8.3.7	OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS	196
8.4	PATIENT ENGAGEMENT & REMOTE MONITORING	197
8.4.1	SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE	198
8.4.1.1	Rising prevalence of chronic diseases to drive market growth	198
8.4.2	TELEHEALTH & REMOTE PATIENT MONITORING	199
8.4.2.1	Ability to monitor and evaluate patients remotely to boost market demand	199
8.4.3	HEALTHCARE ASSISTANCE ROBOTS	199

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4.3.1 Advancements in robotics and artificial intelligence (AI) to boost market demand 199
- 8.4.4 MEDICATION REMINDERS 200
 - 8.4.4.1 Increasing adoption of smartphone applications and IoT devices to surge market demand 200
- 8.4.5 PATIENT EDUCATION & EMPOWERMENT 201
 - 8.4.5.1 Need to improve treatment adherence and enhance self-management to drive market growth 201
- 8.4.6 OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS 202
- 8.5 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE 203
 - 8.5.1 RECURRENCE MONITORING 204
 - 8.5.1.1 Need to predict recurrence of cancer to drive market 204
 - 8.5.2 LONG-TERM OUTCOME PREDICTION 204
 - 8.5.2.1 Ability to predict long-term health outcomes and enhance patient care to drive market 204
 - 8.5.3 MENTAL HEALTH & SUPPORT SYSTEMS 205
 - 8.5.3.1 Need to help patients cope with mental strain to drive market 205
- 8.6 PHARMACY MANAGEMENT 206
 - 8.6.1 EPRESCRIBING 207
 - 8.6.1.1 Need to improve safety and efficiency in prescription to drive market 207
 - 8.6.2 MEDICATION MANAGEMENT 207
 - 8.6.2.1 Ability to predict adverse drug reactions by patient data analysis to drive market 207
 - 8.6.3 PHARMACY AUDIT & ANALYSIS 208
 - 8.6.3.1 Need for effective and efficient operation of pharmacies to drive market 208
 - 8.6.4 OTHER PHARMACY MANAGEMENT FUNCTIONS 209
- 8.7 DATA MANAGEMENT & ANALYTICS 210
 - 8.7.1 ABILITY OF DATA MANAGEMENT & ANALYTICS TO HELP HEALTHCARE ORGANIZATIONS MAKE INFORMED DECISIONS TO BOOST MARKET 210
- 8.8 ADMINISTRATIVE 210
 - 8.8.1 PATIENT REGISTRATION & SCHEDULING 212
 - 8.8.1.1 Need to optimize patient registration process for smoother operations to drive market 212
 - 8.8.2 PATIENT ELIGIBILITY & AUTHORIZATION 213
 - 8.8.2.1 Need to reduce administrative burden to drive market 213
 - 8.8.3 BILLING & CLAIMS MANAGEMENT 214
 - 8.8.3.1 Need to make billing process more accurate, efficient, and transparent to drive market 214
 - 8.8.4 WORKFORCE MANAGEMENT 215
 - 8.8.4.1 Need for effective staff management to drive market 215
 - 8.8.5 SUPPLY CHAIN & INVENTORY MANAGEMENT 216
 - 8.8.5.1 Ability to make better procurement decisions to fuel market 216
 - 8.8.6 COMPLIANCE & DOCUMENTATION 217
 - 8.8.6.1 Need to reduce manual paperwork and errors to drive market 217
 - 8.8.7 HEALTHCARE WORKFLOW MANAGEMENT 218
 - 8.8.7.1 Need to optimize and automate processes within healthcare facilities to drive market 218
 - 8.8.8 ASSET MANAGEMENT 219
 - 8.8.8.1 Ability to optimize use and allocation of resources to drive market 219
 - 8.8.9 CUSTOMER RELATIONSHIP MANAGEMENT 220
 - 8.8.9.1 Enhancing patient engagement and retention through AI-driven CRM systems to boost market 220
 - 8.8.10 FRAUD DETECTION & RISK MANAGEMENT 221
 - 8.8.10.1 Need to enhance security in healthcare systems to drive market demand 221
 - 8.8.11 CYBERSECURITY 222
 - 8.8.11.1 Enhancing healthcare cybersecurity with AI-driven threat detection and risk management to fuel growth 222

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.8.12	OTHER ADMINISTRATIVE FUNCTIONS	223
9	AI IN HEALTHCARE MARKET, BY APPLICATION	224
9.1	INTRODUCTION	225
9.2	CLINICAL APPLICATIONS	225
9.2.1	ABILITY OF AI TO IMPROVE DIAGNOSTICS, TREATMENT, AND PATIENT CARE TO DRIVE MARKET GROWTH	225
9.3	NON-CLINICAL APPLICATIONS	227
9.3.1	ABILITY OF AI TO REDUCE ADMINISTRATIVE BURDEN AND ENSURE BETTER RESOURCE ALLOCATION TO FUEL GROWTH	227
10	AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL	229
10.1	INTRODUCTION	230
10.2	ON-PREMISE MODELS	230
10.2.1	ENHANCED DATA SECURITY AND COMPLIANCE TO PROPEL ADOPTION OF ON-PREMISE AI MODELS	230
10.3	CLOUD-BASED MODELS	231
10.3.1	SCALABILITY AND AUTOMATION OF CLOUD-BASED AI PLATFORMS TO RESHAPE HEALTHCARE DELIVERY GLOBALLY	231
10.4	HYBRID MODELS	233
10.4.1	FLEXIBILITY FOR DIVERSE APPLICATIONS TO BOOST DEMAND FOR HYBRID MODELS	233
11	ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET, BY TOOL	234
11.1	INTRODUCTION	235
11.2	MACHINE LEARNING	235
11.2.1	DEEP LEARNING	237
11.2.1.1	Convolutional neural networks (CNN)	239
11.2.1.1.1	Growing demand for advance medical imaging and diagnostics to drive market growth	239
11.2.1.2	Recurrent neural networks (RNN)	240
11.2.1.2.1	Ability of RNN to enhance predictive analytics in healthcare to boost market	240
11.2.1.3	Generative adversarial networks (GAN)	240
11.2.1.3.1	Ability to transform data scarcity and privacy in AI-driven healthcare to drive demand for GAN	240
11.2.1.4	Graph neural networks (GNN)	241
11.2.1.4.1	Ability of GNN to revolutionize relational insights in healthcare analytics to fuel growth	241
11.2.1.5	Other deep learning tools	242
11.2.2	SUPERVISED LEARNING	242
11.2.2.1	Need to drive precision and efficiency in healthcare to support adoption of supervised learning tools	242
11.2.3	REINFORCEMENT LEARNING	243
11.2.3.1	Wide usage of reinforcement learning models for real-time and adaptive healthcare solutions to support market growth	243
11.2.4	UNSUPERVISED LEARNING	244
11.2.4.1	Ability of unsupervised learning to drive innovation in healthcare analytics to propel market	244
11.2.5	OTHER MACHINE LEARNING TOOLS	245
11.3	NATURAL LANGUAGE PROCESSING (NLP)	246
11.3.1	SENTIMENT ANALYSIS	247
11.3.1.1	Enhanced patient experience and operational insights to spur demand for sentiment analysis	247
11.3.2	PATTERN & IMAGE RECOGNITION	248
11.3.2.1	Increased precision in clinical decision-making associated with pattern & image recognition to aid market	248
11.3.3	AUTO CODING	248
11.3.3.1	Advantages such as improved medical billing and administrative efficiency to boost market	248
11.3.4	CLASSIFICATION & CATEGORIZATION	249
11.3.4.1	Ability of classification & categorization to organize healthcare data for better outcomes to propel market	249
11.3.5	TEXT ANALYTICS	250

- 11.3.5.1 Ability to transform unstructured data into actionable healthcare insights to fuel growth 250
- 11.3.6 SPEECH RECOGNITION 250
 - 11.3.6.1 Improved speech recognition advancing real-time documentation and accessibility to drive demand 250
- 11.4 CONTEXT-AWARE COMPUTING 251
 - 11.4.1 DEVICE CONTEXT 252
 - 11.4.1.1 Real-time monitoring and decision-making to contribute to market growth 252
 - 11.4.2 USER CONTEXT 253
 - 11.4.2.1 Personalized healthcare and adaptive workflows to drive demand 253
 - 11.4.3 PHYSICAL CONTEXT 254
 - 11.4.3.1 Location-based services associated with physical context to generate demand 254
- 11.5 GENERATIVE AI 255
 - 11.5.1 ABILITY OF GENERATIVE AI MODELS TO MIMIC DISEASE PROGRESSION TO DRIVE MARKET 255
- 11.6 COMPUTER VISION 256
 - 11.6.1 ABILITY TO DETECT ABNORMALITIES SUCH AS TUMORS TO FUEL ADOPTION 256
- 11.7 IMAGE ANALYSIS 257
 - 11.7.1 NEED TO STREAMLINE DOCUMENT MANAGEMENT TO PROPEL MARKET 257
- 12 AI IN HEALTHCARE MARKET, BY END USER 259
 - 12.1 INTRODUCTION 260
 - 12.2 HEALTHCARE PROVIDERS 260
 - 12.2.1 HOSPITALS & CLINICS 263
 - 12.2.1.1 Growing need to improve profitability of healthcare to drive use of AI-based healthcare solutions in hospitals 263
 - 12.2.2 AMBULATORY CARE CENTERS 264
 - 12.2.2.1 Supportive government norms and incentives for HCIT solutions and services to drive market growth 264
 - 12.2.3 HOME HEALTHCARE AGENCIES & ASSISTED LIVING FACILITIES 265
 - 12.2.3.1 Growing need for long-term home care to drive market growth 265
 - 12.2.4 DIAGNOSTIC & IMAGING CENTERS 266
 - 12.2.4.1 Growing burden of various chronic diseases to propel market growth 266
 - 12.2.5 PHARMACIES 268
 - 12.2.5.1 Advantages of workflow improvements and error reduction to drive AI-based healthcare solution adoption in pharmacies 268
 - 12.2.6 OTHER HEALTHCARE PROVIDERS 269
 - 12.3 HEALTHCARE PAYERS 269
 - 12.3.1 PUBLIC PAYERS 270
 - 12.3.1.1 Focus on developing outcome-based payment models to drive demand for payer solutions 270
 - 12.3.2 PRIVATE PAYERS 271
 - 12.3.2.1 Possible increases in operational efficiency to boost demand among private payers 271
 - 12.4 PATIENTS 272
 - 12.4.1 RISE IN USE OF AI IN MENTAL HEALTH SUPPORT APPLICATIONS THROUGH CHATBOTS AND VIRTUAL THERAPISTS TO BOOST MARKET 272
 - 12.5 OTHER END USERS 273
- 13 AI IN HEALTHCARE MARKET, BY REGION 275
 - 13.1 INTRODUCTION 276
 - 13.2 NORTH AMERICA 277
 - 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 279
 - 13.2.2 US 293
 - 13.2.2.1 Rising adoption of advanced medical imaging and regulatory support to drive market 293

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.3	CANADA	307
13.2.3.1	Growing burden of chronic diseases and availability of research grants for AI to drive market growth	307
13.3	EUROPE	321
13.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	321
13.3.2	GERMANY	335
13.3.2.1	Advanced healthcare system and government efforts to drive growth	335
13.3.3	UK	348
13.3.3.1	Government support and new AI platform emergence to boost market	348
13.3.4	FRANCE	360
13.3.4.1	Thriving AI ecosystem and strategic partnerships to boost healthcare innovation	360
13.3.5	ITALY	374
13.3.5.1	Regulatory reforms, strategic investments, and aging population to propel growth	374
13.3.6	SPAIN	388
13.3.6.1	Established network of research centers to propel market	388
13.3.7	REST OF EUROPE	402
13.4	ASIA PACIFIC	416
13.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	418
13.4.2	CHINA	432
13.4.2.1	Expanding AI applications in medical imaging and diagnostics to drive market growth	432
13.4.3	JAPAN	445
13.4.3.1	Strong healthcare infrastructure to drive uptake of advanced AI	445
13.4.4	INDIA	458
13.4.4.1	Favorable government initiatives for R&D investments to drive market	458
13.4.5	REST OF ASIA PACIFIC	471
13.5	LATIN AMERICA	483
13.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	484
13.5.2	BRAZIL	497
13.5.2.1	AI initiatives to drive healthcare innovation and accessibility	497
13.5.3	MEXICO	508
13.5.3.1	AI to revolutionize healthcare delivery and outcomes, focusing on accessibility, efficiency, and innovation	508
13.5.4	REST OF LATIN AMERICA	521
13.6	MIDDLE EAST & AFRICA	533
13.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	534
13.6.2	GCC COUNTRIES	547
13.6.2.1	AI-driven innovations and rise in healthcare investments to propel market growth	547
13.6.3	REST OF THE MIDDLE EAST & AFRICA	561
14	COMPETITIVE LANDSCAPE	574
14.1	INTRODUCTION	574
14.2	KEY PLAYER STRATEGY/RIGHT TO WIN	574
14.2.1	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN HEALTHCARE MARKET	575
14.3	REVENUE ANALYSIS, 2020-2024	578
14.4	MARKET SHARE ANALYSIS, 2024	579
14.4.1	RANKING OF KEY MARKET PLAYERS	582
14.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	583
14.5.1	STARS	583
14.5.2	EMERGING LEADERS	583
14.5.3	PERVASIVE PLAYERS	583

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.5.4	PARTICIPANTS	583
14.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	585
14.5.5.1	Company footprint	585
14.5.5.2	Regional footprint	586
14.5.5.3	Application footprint	587
14.5.5.4	Tool footprint	588
14.5.5.5	Function footprint	589
14.5.5.6	Offering footprint	590
14.5.5.7	Deployment footprint	591
14.5.5.8	End-user footprint	592
14.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	593
14.6.1	PROGRESSIVE COMPANIES	593
14.6.2	RESPONSIVE COMPANIES	593
14.6.3	DYNAMIC COMPANIES	593
14.6.4	STARTING BLOCKS	593
14.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	595
14.6.5.1	Detailed list of key startups/SMEs	595
14.6.5.2	Company footprint (startups/SMEs)	596
?		
14.7	COMPANY VALUATION AND FINANCIAL METRICS	596
14.7.1	FINANCIAL METRICS	596
14.7.2	COMPANY VALUATION	597
14.8	BRAND/PRODUCT COMPARISON	598
14.9	COMPETITIVE SCENARIO	599
14.9.1	PRODUCT LAUNCHES	599
14.9.2	DEALS	600
14.9.3	OTHER DEVELOPMENTS	601
15	COMPANY PROFILES	603
15.1	KEY PLAYERS	603
15.1.1	KONINKLIJKE PHILIPS N.V.	603
15.1.1.1	Business overview	603
15.1.1.2	Products & services offered	604
15.1.1.3	Recent developments	607
15.1.1.3.1	Product launches	607
15.1.1.3.2	Deals	608
15.1.1.3.3	Expansions	610
15.1.1.3.4	Other developments	611
15.1.1.4	MnM view	611
15.1.1.4.1	Right to win	611
15.1.1.4.2	Strategic choices	612
15.1.1.4.3	Weaknesses & competitive threats	612
15.1.2	MICROSOFT CORPORATION	613
15.1.2.1	Business overview	613
15.1.2.2	Products & services offered	615
15.1.2.3	Recent developments	616
15.1.2.3.1	Product launches	616
15.1.2.3.2	Deals	617

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.2.4□MnM view□619
- 15.1.2.4.1□Right to win□619
- 15.1.2.4.2□Strategic choices□619
- 15.1.2.4.3□Weaknesses & competitive threats□620
- 15.1.3□NVIDIA CORPORATION□620
- 15.1.3.1□Business overview□620
- 15.1.3.2□Products & services offered□621
- 15.1.3.3□Recent developments□622
- 15.1.3.3.1□Product launches□622
- 15.1.3.3.2□Deals□623
- 15.1.3.4□MnM view□624
- 15.1.3.4.1□Right to win□624
- 15.1.3.4.2□Strategic choices□624
- 15.1.3.4.3□Weaknesses & competitive threats□624
- 15.1.4□SIEMENS HEALTHINEERS AG□625
- 15.1.4.1□Business overview□625
- 15.1.4.2□Products & services offered□627
- 15.1.4.3□Recent developments□628
- 15.1.4.3.1□Product launches & enhancements□628
- 15.1.4.3.2□Deals□628
- 15.1.4.3.3□Other developments□630
- 15.1.4.4□MnM view□630
- 15.1.4.4.1□Right to win□630
- 15.1.4.4.2□Strategic choices□630
- 15.1.4.4.3□Weaknesses & competitive threats□631
- 15.1.5□GE HEALTHCARE□632
- 15.1.5.1□Business overview□632
- 15.1.5.2□Products & services offered□634
- 15.1.5.3□Recent developments□635
- 15.1.5.3.1□Deals□635
- 15.1.5.3.2□Other developments□636
- 15.1.5.4□MnM view□636
- 15.1.5.4.1□Right to win□636
- 15.1.5.4.2□Strategic choices□637
- 15.1.5.4.3□Weaknesses & competitive threats□637
- 15.1.6□EPIC SYSTEMS CORPORATION□638
- 15.1.6.1□Business overview□638
- 15.1.6.2□Products & services offered□638
- 15.1.6.3□Recent developments□639
- 15.1.6.3.1□Deals□639
- 15.1.7□ORACLE CORPORATION□640
- 15.1.7.1□Business overview□640
- 15.1.7.2□Products & services offered□641
- 15.1.7.3□Recent developments□642
- 15.1.7.3.1□Product launches□642
- 15.1.7.3.2□Deals□643
- 15.1.7.3.3□Expansions□644

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.8 VERADIGM INC. 645
 - 15.1.8.1 Business overview 645
 - 15.1.8.2 Products & services offered 646
 - 15.1.8.3 Recent developments 647
 - 15.1.8.3.1 Deals 647
- 15.1.9 AMAZON WEB SERVICES, INC. 648
 - 15.1.9.1 Business overview 648
 - 15.1.9.2 Products & services offered 649
 - 15.1.9.3 Recent developments 650
 - 15.1.9.3.1 Product launches 650
 - 15.1.9.3.2 Deals 651
 - 15.1.9.3.3 Expansions 652
- 15.1.10 MERATIVE 653
 - 15.1.10.1 Business overview 653
 - 15.1.10.2 Products & services offered 653
 - 15.1.10.3 Recent developments 654
 - 15.1.10.3.1 Product launches 654
 - 15.1.10.3.2 Deals 654
- 15.1.11 IBM 655
 - 15.1.11.1 Business overview 655
 - 15.1.11.2 Products & services offered 656
 - 15.1.11.3 Recent developments 657
 - 15.1.11.3.1 Deals 657
- 15.1.12 MEDTRONIC 658
 - 15.1.12.1 Business overview 658
 - 15.1.12.2 Products & services offered 659
 - 15.1.12.3 Recent developments 660
 - 15.1.12.3.1 Product launches 660
 - 15.1.12.3.2 Deals 661
- 15.1.13 GOOGLE 662
 - 15.1.13.1 Business overview 662
 - 15.1.13.2 Products & services offered 663
 - 15.1.13.3 Recent developments 664
 - 15.1.13.3.1 Product launches 664
 - 15.1.13.3.2 Deals 665
 - 15.1.13.3.3 Other developments 667
- 15.1.14 SOPHIA GENETICS 668
 - 15.1.14.1 Business overview 668
 - 15.1.14.2 Products & services offered 669
 - 15.1.14.3 Recent developments 669
 - 15.1.14.3.1 Product launches 669
 - 15.1.14.3.2 Deals 670
 - 15.1.14.3.3 Other developments 671
- 15.1.15 JOHNSON & JOHNSON SERVICES, INC. 672
 - 15.1.15.1 Business overview 672
 - 15.1.15.2 Products & services offered 673

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.1.15.3	Recent developments	674
15.1.15.3.1	Other developments	674
15.1.15.3.2	Deals	674
15.1.16	TEMPUS AI, INC.	675
15.1.16.1	Business overview	675
15.1.16.2	Products & services offered	676
15.1.16.3	Recent developments	677
15.1.16.3.1	Product launches	677
15.1.16.3.2	Deals	678
15.1.17	CONCERTAI	679
15.1.17.1	Business overview	679
15.1.17.2	Products & services offered	679
15.1.17.3	Recent developments	680
15.1.17.3.1	Product launches	680
15.1.17.3.2	Deals	681
15.1.18	SOLVENTUM CORPORATION	683
15.1.18.1	Business overview	683
15.1.18.2	Products & services offered	684
15.1.18.3	Recent developments	685
15.1.18.3.1	Deals	685
15.1.18.3.2	Other developments	685
15.1.19	COGNIZANT	686
15.1.19.1	Business overview	686
15.1.19.2	Products & services offered	688
15.1.19.3	Recent developments	688
15.1.19.3.1	Product launches	688
15.1.19.3.2	Deals	689
15.1.20	VIZ.AI, INC.	690
15.1.20.1	Business overview	690
15.1.20.2	Products & services offered	690
15.1.20.3	Recent developments	691
15.1.20.3.1	Product launches	691
15.1.20.3.2	Deals	692
15.1.20.3.3	Other developments	694
15.1.21	RIVERAIN TECHNOLOGIES	695
15.1.21.1	Business overview	695
15.1.21.2	Products & services offered	695
15.1.21.3	Recent developments	696
15.1.21.3.1	Deals	696
?		
15.2	OTHER PLAYERS	697
15.2.1	QVENTUS	697
15.2.2	QURE.AI	698
15.2.3	ATOMWISE INC.	699
15.2.4	ENLITIC	700
15.2.5	SEGMED	700
16	APPENDIX	701

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.1 DISCUSSION GUIDE 701

16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 708

16.3 CUSTOMIZATION OPTIONS 710

16.4 RELATED REPORTS 710

16.5 AUTHOR DETAILS 711

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Artificial Intelligence (AI) in Healthcare Market by Offering (Integrated), Function (Diagnosis, Genomic, Precision Medicine, Radiation, Immunotherapy, Pharmacy, Supply Chain), Application (Clinical), End User (Hospitals), Region - Global Forecast to 2030

Market Report | 2025-05-09 | 713 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature